Article
Phase I/II study of amrubicin in combination with S-1 as second-line chemotherapy for non-small-cell lung cancer without EGFR mutation.
Cancer chemotherapy and pharmacology - 1 Mar 2013
Murakami Shuji, Oshita Fumihiro, Sugiura Makiko, Kondo Tetsuro, Saito Haruhiro, Yamada Kouzo
Abstract excerpt
INTRODUCTION: Both amrubicin (Am) and S-1 are effective against non-small-cell lung cancer (NSCLC), and preclinical studies have demonstrated that the effect of tegafur/uracil, the original compound of S-1, in combination with Am significantly inhibits tumor growth. METHODS: We conducted a phase I/II study of Am and S-1 against pretreated NSCLC without EGFR mutation. We fixed the dose of S-1 at 40 mg/m(2) on days...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.